A Mountain View biotechnology company says an experimental skin cream reduced molecular markers of aging and inflammation in a small early human trial, though the findings are preliminary and have not been published in a peer-reviewed journal.
Rubedo Life Sciences tested its investigational drug, RLS-1496, in patients with eczema and other skin conditions. In an analysis of 11 paired skin samples from patients with atopic dermatitis, the company reported that four weeks of treatment was associated with an average 2.1-year decrease in measured epigenetic skin age, an estimate derived from age-related changes in DNA.
Rubedo CEO Dr. Frederick Beddingfield called the results significant and said they justify further study. “This is one of the few drugs developed for aging in general and with AI to show positive data in humans in multiple indications and to show a reduction in skin age,” he told Fox News Digital. He said he expects the early signals to translate into “clinical improvements with longer-term treatment.”
The skin-aging data were presented at a scientific conference but have not yet undergone peer review.
How the drug is designed to work
RLS-1496 targets senescent cells, which are aging or damaged cells that stop dividing but can release inflammatory substances. The drug works by targeting a protein called GPX4, which helps cells respond to stress. Researchers are examining whether blocking GPX4 clears out damaged cells while allowing healthier ones to survive.
Beddingfield described the strategy as aiming at cellular aging itself rather than its surface effects. “It’s a bit like ‘what does not kill you makes you stronger’ for those surviving cells,” he said.
According to the company, skin samples showed a 10% increase in a type of collagen that supports skin structure, and blood tests showed lower levels of several inflammation markers. The company has not established what those changes mean for patients’ overall health.
Limitations in the data
The study behind the skin-aging claim involved just 11 paired samples and measured biological markers rather than visible or functional improvements in skin. Treatment lasted only four weeks, leaving open whether any effect persists over time. The research was funded by Rubedo itself, and the findings have not been published as a full peer-reviewed study.
“Our next trial will treat for several months,” Beddingfield said.
The company is also testing the same drug for actinic keratosis, a precancerous skin condition caused by sun exposure. In a separate open-label study of 22 patients, Rubedo reported a 49% average reduction in lesions after 28 days, comparing treated forearms against untreated forearms on the same patients rather than against a placebo cream.
Rubedo said the cream caused minimal skin irritation and that the drug was detected in the blood of very few participants. “With topical application, we have seen very little risk,” Beddingfield said. “Local irritation is rarely seen and generally mild when it occurs, and no one has discontinued treatment to date. Very few subjects show any drug in their blood after skin application.”
The company has also begun an early-stage trial of the drug for androgenetic alopecia, or pattern hair loss. Beddingfield estimated that any FDA approval remains three to four years away, pending larger clinical trials.
Add comment